These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11783955)

  • 21. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
    Williams RT; Sherr CJ
    Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
    Coppo P; Dusanter-Fourt I; Millot G; Nogueira MM; Dugray A; Bonnet ML; Mitjavila-Garcia MT; Le Pesteur D; Guilhot F; Vainchenker W; Sainteny F; Turhan AG
    Oncogene; 2003 Jun; 22(26):4102-10. PubMed ID: 12821944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.
    Huntly BJ; Shigematsu H; Deguchi K; Lee BH; Mizuno S; Duclos N; Rowan R; Amaral S; Curley D; Williams IR; Akashi K; Gilliland DG
    Cancer Cell; 2004 Dec; 6(6):587-96. PubMed ID: 15607963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.
    Kronenwett R; Butterweck U; Steidl U; Kliszewski S; Neumann F; Bork S; Blanco ED; Roes N; Gräf T; Brors B; Eils R; Maercker C; Kobbe G; Gattermann N; Haas R
    Oncogene; 2005 Aug; 24(34):5313-24. PubMed ID: 15806158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
    Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
    Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathogenetic mechanisms of chronic myeloid leukemia and the antiproliferative effects of alpha and gamma interferons].
    Cazzola M; Pedrazzoli P; Bergamaschi G; Buonanno C; Cuomo A; D'Uva R; Ponchio L; Rosti V; Zappone E; Ascari E
    Haematologica; 1990; 75 Suppl 4():20-7. PubMed ID: 2127411
    [No Abstract]   [Full Text] [Related]  

  • 27. Cancer stem cells and the cellular hierarchy in haematological malignancies.
    Johnsen HE; Kjeldsen MK; Urup T; Fogd K; Pilgaard L; Boegsted M; Nyegaard M; Christiansen I; Bukh A; Dybkaer K
    Eur J Cancer; 2009 Sep; 45 Suppl 1():194-201. PubMed ID: 19775618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pleiotropic p27(Kip1), BCR-ABL and leukemic stem cell: the trio in concert.
    Sengupta A; Banerjee S
    Leukemia; 2007 Dec; 21(12):2559-61. PubMed ID: 17611557
    [No Abstract]   [Full Text] [Related]  

  • 29. Miscreant myeloproliferative disorder stem cells.
    Jamieson CH; Barroga CF; Vainchenker WP
    Leukemia; 2008 Nov; 22(11):2011-9. PubMed ID: 18923436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular-genetic aspects of leukaemogenesis.
    Fey MF
    Schweiz Med Wochenschr Suppl; 1991; 43():33-9. PubMed ID: 1843036
    [No Abstract]   [Full Text] [Related]  

  • 31. Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia.
    Crescenzi B; Sacchi S; Marasca R; Temperani P; La Starza R; Matteucci C; Bonacorsi G; Romoli S; Martelli MF; Mecucci C; Emilia G
    Leukemia; 2002 May; 16(5):955-6. PubMed ID: 11986962
    [No Abstract]   [Full Text] [Related]  

  • 32. CML: a model disease with a defined oncogenic driver.
    Hao Z; Cowell JK
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):247-8. PubMed ID: 21475133
    [No Abstract]   [Full Text] [Related]  

  • 33. Biologically-based risk estimation for radiation-induced chronic myeloid leukemia.
    Radivoyevitch T; Hoel DG
    Radiat Environ Biophys; 2000 Sep; 39(3):153-9. PubMed ID: 11095145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-transplantation chronic myeloid leukemia.
    le Coutre P; Schwarz M; Daniel P; Dörken B
    Clin Adv Hematol Oncol; 2011 Aug; 9(8):627-9. PubMed ID: 22236992
    [No Abstract]   [Full Text] [Related]  

  • 35. [Properties of leukemic stem cells and treatment strategy for the cure of chronic myelogenous leukemia].
    Minami Y
    Rinsho Ketsueki; 2013 Jun; 54(6):552-8. PubMed ID: 23823094
    [No Abstract]   [Full Text] [Related]  

  • 36. Exciting times for our field and the Journal.
    Humphries RK
    Exp Hematol; 2011 Mar; 39(3):271. PubMed ID: 21277347
    [No Abstract]   [Full Text] [Related]  

  • 37. Stability analysis of a simplified yet complete model for chronic myelogenous leukemia.
    Doumic-Jauffret M; Kim PS; Perthame B
    Bull Math Biol; 2010 Oct; 72(7):1732-59. PubMed ID: 20077027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimation of the target stem-cell population size in chronic myeloid leukemogenesis.
    Radivoyevitch T; Ramsey MJ; Tucker JD
    Radiat Environ Biophys; 1999 Sep; 38(3):201-6. PubMed ID: 10525957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haemangioblast origin of chronic myeloid leukaemia?
    Green AR
    Lancet; 2000 May; 355(9216):1659-60. PubMed ID: 10905236
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic background affects susceptibility to tumoral stem cell reprogramming.
    García-Ramírez I; Ruiz-Roca L; Martín-Lorenzo A; Blanco O; García-Cenador MB; García-Criado FJ; Vicente-Dueñas C; Sánchez-García I
    Cell Cycle; 2013 Aug; 12(15):2505-9. PubMed ID: 23839033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.